MOONLAKE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against MoonLake Immunotherapeutics and Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics for allegedly misleading investors regarding its drug candidate sonelokimab, leading to significant financial losses after disappointing trial results were announced [7]. Allegation Details - The lawsuit claims that MoonLake promoted sonelokimab as superior to competing monoclonal antibodies while failing to disclose that it targeted the same molecules as UCB's BIMZELX and did not demonstrate proven superiority [7]. - Following the announcement of Phase 3 trial results on September 28, 2025, which showed that sonelokimab did not match the efficacy of BIMZELX, MoonLake's stock price dropped nearly 90%, resulting in substantial losses for investors [7]. Next Steps - Investors who purchased MoonLake shares between March 10, 2024, and September 29, 2025, and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information and to discuss their legal rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is December 15, 2025 [7]. Company Information - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across state and federal courts [5].